ASXL1 and myeloid leukemia: Most of the studies on human ASXL1 function are in the context of myeloid leukemia and propose that truncating ASXL1 mutations result in haploinsufficiency (11, 36), dominant-negative, or gain-of-function effects (31, 37, 38).